Johnson & Johnson posted a 6.5% year-over-year increase in sales of its Stelara (ustekinumab) treatment for pediatric patients with juvenile psoriatic arthritis in 2022, to
The pharmaceutical company Novartis will invest 50 million dollars in clinical research in Mexico in the next triennium. All drug candidates undergo proof-of-concept trials to
Johnson & Johnson posted a 6.5% year-over-year increase in sales of its Stelara (ustekinumab) treatment for pediatric patients with juvenile psoriatic arthritis in 2022, to
The pharmaceutical company Novartis will invest 50 million dollars in clinical research in Mexico in the next triennium. All drug candidates undergo proof-of-concept trials to
Redacción: 7224059128
info@opportimes.com
